复星医药(02196.HK)：复迈宁®联合疗法临床试验申请获批

Core Viewpoint - Fosun Pharma has received approval from the National Medical Products Administration to conduct clinical trials for its drug, Rumaine (generic name: Luwotemib), in combination with Anlotinib for advanced non-small cell lung cancer (NSCLC) patients with KRAS mutations [1] Group 1 - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is responsible for the clinical trial [1] - The company plans to initiate a Phase II clinical trial for the drug in mainland China once conditions are met [1]